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Abstract
Background: African Americans experience significant tobacco-related health disparities despite the fact that over
half of African American smokers are light smokers (use ≤10 cigarettes per day). African Americans have been
under-represented in smoking cessation research, and few studies have evaluated treatment for light smokers. This
paper describes the study design, measures, and baseline characteristics from Kick It at Swope III (KIS-III), the first
treatment study of bupropion for African American light smokers.
Methods: Five hundred forty African American light smokers were randomly assigned to receive bupropion
(150mg bid) (n = 270) or placebo (n = 270) for 7 weeks. All participants received written materials and health
education counseling. Participants responded to survey items and provided blood samples for evaluation of
phenotype and genotype of CYP2A6 and CYP2B6 enzymes involved in nicotine and bupropion metabolism.
Primary outcome was cotinine-verified 7-day point prevalence smoking abstinence at Week 26 follow-up.
Results: Of 2,628 individuals screened, 540 were eligible, consented, and randomized to treatment. Participants
had a mean age of 46.5 years and 66.1% were women. Participants smoked an average of 8.0 cigarettes per day,
had a mean exhaled carbon monoxide of 16.4ppm (range 1-55) and a mean serum cotinine of 275.8ng/ml. The
mean Fagerström Test for Nicotine Dependence was 3.2, and 72.2% of participants smoked within 30 minutes of
waking. The average number of quit attempts in the past year was 3.7 and 24.2% reported using pharmacotherapy
in their most recent quit attempt. Motivation and confidence to quit were high.
Conclusion: KIS-III is the first study designed to examine both nicotine and bupropion metabolism, evaluating
CYP2A6 and CYP2B6 phenotype and genotype in conjunction with psychosocial factors, in the context of
treatment of African American light smokers. Of 1629 smokers screened for study participation, only 18 (1.1%) were
ineligible to participate in the study because they refused blood draws, demonstrating the feasibility of recruiting
and enrolling African American light smokers into a clinical treatment trial involving biological data collection and
genetic analyses. Future evaluation of individual factors associated with treatment outcome will contribute to
advancing tailored tobacco use treatment with the goal of enhancing treatment and reducing health disparities for
African American light smokers.
Trial Registration: ClinicalTrials.gov: NCT00666978
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Tobacco use remains the leading preventable cause of
disease and death in the United States [1]. Differences in
patterns of tobacco use, access to treatment, and treat-
ment outcomes between African American and white
smokers have been well documented [2-7]. Compared to
white smokers, African American smokers consume
fewer cigarettes per day and are more likely to be classi-
fied as “light” smokers, smoking 10 or fewer cigarettes
per day [8-11]. However, African American smokers are
more likely to smoke high-tar and mentholated cigarettes
[12,13], to inhale more deeply [14], and to have a slower
rate of nicotine metabolism [15] and show higher levels
of cotinine per cigarette smoked [4,16,17]. Unfortunately,
African American smokers are less likely to receive treat-
ment, have poorer treatment outcomes, and suffer a
disproportionately greater share of tobacco-related mor-
bidity and mortality [1], making treatment of these smo-
kers a continued public health priority. African American
smokers historically have been under-represented in
smoking cessation research and few studies have focused
on treating light smokers [18,19].
The current paper describes the study design and
baseline characteristics from Kick It at Swope III (KIS-
III), a clinical trial of bupropion and health education
counseling for African American light smokers. KIS-III
is the third in a series of studies aimed at enhancing
tobacco use treatment for African American smokers.
The first KIS-I trial [20] was a double-blind, placebo-
controlled trial that demonstrated the efficacy of
sustained release bupropion in African American mod-
erate to heavy smokers, those who smoked 10 or more
cigarettes per day (cpd). Because over 50% of African
American smokers are light smokers, the second KIS
trial (KIS-II) focused on treating light smokers (1-10
cpd) and evaluated nicotine gum compared to placebo
in combination with either motivational interviewing
(MI) or health education (HE) counseling using a 2x2
factorial design [21,22]. Findings from KIS-II showed
no benefit of nicotine gum, but demonstrated a dou-
bling in rates of abstinence for smokers who received
HE compared to MI counseling [22]. The lack of
response to nicotine replacement therapy may have
been due to under-dosing related to low dose of drug
used (2mg rather than 4mg), insufficient frequency of
dosing, or poor adherence. For these reasons, a non-
nicotine medication was considered for the present
trial of African American light smokers. Of note, we
explored more completely the issues of biomarkers and
found neither carbon monoxide nor cotinine were
strongly associated with self-reported smoking level in
this light smoking population [4]. We also found that
abstinence was influenced by genetically variable rates
of nicotine metabolism [15].
The present KIS-III study was designed to build upon
KIS-I and KIS-II findings. Because bupropion was found
to be effective in African American moderate to heavy
smokers, KIS-III was designed to extend this evaluation
within African American light smokers, in combination
with effective HE counseling. Based on prior research,
bupropion treatment is expected to reduce the reward-
ing effects of smoking and aid withdrawal reduction for
smokers independent of smoking level. In addition, we
continued investigation of genetic and pharmacokinetic
influences on cessation in KIS-III.
Because genetic, sociocultural, and pharmacological
determinants of smoking vary across racial and ethnic
groups and may impact tobacco use treatment, empiri-
cal evaluation of these factors in the context of smok-
ing cessation intervention has been recommended
[15,16,23]. The consistent disparity of finding higher
cotinine levels per cigarette in African American smo-
kers is likely due to greater intake of nicotine per cigar-
ette smoked combined with slower nicotine metabolism
[4,17]. The enzyme CYP2A6 [24,25] and genetic varia-
tion in CYP2A6 is associated with multiple smoking
behaviors including cessation, as well as tobacco-related
disease risk [25-28]. Genetic variation in the CYP2B6
gene, coding the enzyme responsible for bupropion
metabolism, is also associated with smoking cessation in
the context of both bupropion and placebo treatment
[29-31]. KIS-III was designed to extend previous studies
of African American smokers by incorporating biological
evaluation of both nicotine and bupropion metabolism,
and the genetic variation in the main metabolic enzymes
CYP2A6 and CYP2B6, in addition to other smoking and
psychosocial factors, within this clinical trial of light
smokers. This paper describes the study design, baseline
characteristics and retention of African-American light
smokers into a smoking cessation treatment trial that
involves biological data collection.
Methods
Study Design
This is a randomized, placebo-controlled study with the
primary aim of evaluating the efficacy of sustained
release bupropion in combination with health education
(HE) counseling for smoking cessation among urban
African-American light smokers. Five hundred and forty
African-American light smokers recruited from the
Kansas City metropolitan area were randomly assigned
to an active bupropion and health education (HE) coun-
seling (Tx) condition (n = 270) or to a placebo and HE
comparison (C) condition (n = 270). The primary out-
come was 7-day point prevalence smoking abstinence at
6 months confirmed with salivary cotinine. The study
was conducted at an urban community-based clinic that
serves predominantly low-income African-American
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posed of African-American community members
assisted in the implementation of the study. The study
procedures were approved and monitored by the Uni-
versity of Kansas Medical Center Human Subjects
Committee.
Study Sample
Participant Recruitment
Recruitment started in December 2007 and ended in
October 2009. The final 6-month follow-up was com-
pleted in May 2010. Participants were recruited through
clinic- and community-based efforts. Clinic-based efforts
included use of fliers, posters, physician letters, phar-
macy inserts and lobby recruitment at the primary study
site, Swope Health Services in Kansas City, two Swope
affiliate clinics, and two regional hospitals (the Univer-
sity of Kansas Medical Center and Truman Medical
Center). Community-based efforts included advertise-
ment through radio, television, and newspapers, infor-
mative presentations at health fairs and libraries, local
businesses and religious organizations, and website com-
munication. Participants received referral cards to distri-
bute to friends who smoked. Newsletters providing
current project information, recruitment and success
stories, and tips for quitting and relapse prevention were
also mailed to participants to share with other smokers.
Eligibility and Screening
Interested individuals contacted us by telephone or
in-person. Study staff provided smokers with detailed
information about the study and offered screening for
eligibility. To be eligible, individuals self-identified
as African-American, were age 18 or older, interested
in stopping smoking, smoked ≤10cpd for ≥ 2y e a r s ,
smoked on ≥25 days in the past month, and were will-
ing to attend 4 clinic visits over the course of 6 months.
They must have smoked for at least 3 years, have a
home address and a functioning telephone number.
Exclusion criteria included current use of bupropion;
use of psychoactive medications; use of nicotine replace-
ment therapy, fluoxetine, clonidine, buspirone, or doxe-
pin in the past 30 days; history of alcohol or substance
abuse within the past year; current drinking of 14 or
more alcoholic drinks per week and/or binge drinking
(5 or more drinks on one occasion) 2 or more times in
the past month; history of seizures or head trauma; his-
tory of bulimia or anorexia nervosa; pregnant (verified
by over the counter pregnancy test kit for women of
child-bearing age only) or contemplating pregnancy;
breast feeding; myocardial infarction in the past 30 days;
use of other forms of tobacco in the past 30 days;
reported use of opiates, cocaine, or stimulants; diabetes
treated with oral hypoglycemics or insulin; planning to
move from the Kansas City metro area in the next
12 months; and having another smoker in the household
enrolled in the study.
Consent and Randomization
Study staff reviewed procedures with individuals who
were eligible to participate in the study and administered
written informed consent to these individuals at the base-
line visit. As part of the consent process, potential parti-
cipants were informed about mandatory collection of
blood samples for DNA analysis and procedures for col-
lecting and handling of the samples. Study staff explained
the rationale for the genetic analysis, i.e. to understand
individual differences in nicotine and bupropion metabo-
lism and smoking behavior among African-American
smokers, and how these factors influenced the likelihood
of successfully stopping smoking. The consent form spe-
cified that (a) analysis of DNA ‘’cannot and will not be
used for my own benefit and no results, even if unfavor-
able, will be forwarded to me,’’ (b) DNA would be stored
for a period of no less than 10 years, (c) participants
could request at any time that their DNA be destroyed,
(d) while results of the study may be published, no identi-
fying information would be included in publications and
confidentiality would be maintained, and (e) blood sam-
ples would not be used to develop a commercial product.
Participants responded yes or no to the question, ‘’Ig i v e
permission for my DNA to be used in future studies
about smoking.’’ Participants also were asked for permis-
sion to be contacted for future studies that might require
additional information. A computer generated random
numbers table was used to randomize participants into
an active bupropion and health education (HE) counsel-
ing (Tx) condition or to a placebo and HE counseling (C)
condition. Both participants and investigators were
blinded to the pharmacotherapy condition.
Intervention
Participants received pharmacotherapy treatment
(bupropion or placebo) for 7 weeks, health education
(HE) counseling through Week 16, and were followed
through Week 26. All participants received Kick It at
Swope: Stop Smoking Guide, a culturally sensitive smok-
ing cessation guide developed for African American
light smokers and used previously [22].
Bupropion
At baseline (Week 0), a research assistant gave each par-
ticipant a 7-week supply of bupropion SR 150 mg (150
mg daily for 3 days, then 150 mg twice daily) or placebo.
All participants received an instruction sheet on effec-
tive use of bupropion. A scheduled quit date was
planned to follow 7 days of pharmacotherapy use.
Adverse events were assessed at Weeks 1, 3, 5, 7, and
16. Serum levels of bupropion were drawn at Week 3
for measurement of concentrations of bupropion and
metabolites.
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Health Education (HE) counseling is an education-based
intervention that incorporates recommendations from
the current tobacco treatment guidelines: giving clear
advice to stop smoking, providing assistance with quit-
ting, and arranging follow-up [18]. In this study, HE
counseling included providing information about the
risks of continued smoking and the benefits of quitting,
developing a quit plan, outlining a concrete quit day
preparation plan, discussing strategies for successful
quitting, building social support, reducing stress, recog-
nizing and managing withdrawal and craving, overcom-
ing barriers to abstinence, and using pharmacotherapy.
Table 1 provides a description of the six HE sessions
provided to participants in both arms of the study in
p e r s o na tW e e k s0 ,1 ,3 ,7 ,a n db yp h o n ea tW e e k s5
and 16. Study staff used semi-structured scripts for HE
sessions to incorporate counseling with use of the Kick
It at Swope: Stop Smoking Guide,b u tw o r k e dt ot a i l o r
information to the individual while assisting participants
in developing personalized stop smoking plans. HE ses-
sions lasted, on average, 15-20 minutes.
Written materials
At baseline, study staff reviewed the Kick It at Swope
Stop Smoking Guide with participants. The 36-page
guide includes information about health consequences
of tobacco use and benefits of quitting, disproportionate
effects of tobacco on African-American smokers,
menthol, light smoking and related risks. Specific strate-
gies to promote abstinence included making a quit plan,
using medication, obtaining social support, managing
withdrawal and craving, exercise and healthy eating,
coping with a lapse and relapse prevention.
Retention Prior to each study visit, study staff com-
pleted telephone calls and sent postcard to all partici-
pants of scheduled appointments. For any missed
session, participants received up to 6 telephone calls to
facilitate rescheduling. Study staff gave each participant
a $20 gift card for completing each in person visit
(Weeks 0, 3, 7) and a $40 card for completing follow-up
at Week 26, in appreciation of participant time and
effort. Remuneration was based on session attendance
and not on smoking status. Staff also distributed small
tokens (e.g., tote bag, t-shirt, museum passes) to partici-
pants for in person and telephone sessions completed
throughout the study.
Measures
Table 2 provides an overview of assessments conducted
over the course of KIS-III. Study staff verbally adminis-
tered all self-report measures.
Demographic measures
Demographic information during the baseline assess-
ment was collected using standardized questionnaires.
This information included age, gender, marital status,
income, employment status and education. Height and
weight were measured to calculate body mass index.
Smoking behavior measures
Baseline assessment of smoking history included current
number of cigarettes smoked per day (CPD), type of cigar-
ette smoked (menthol or non-menthol), age when first
smoked, age when started smoking regularly, quitting and
relapse history, reason for most recent relapse, and imple-
mentation of home smoking restrictions. Timeline follow
back [32] was employed to assess individual patterns of
smoking over the past week. Participants rated motivation
and confidence for quitting on a ten point scale, with
higher scores reflecting greater motivation or confidence.
Nicotine dependence was measured using the Fagerström
Test of Nicotine Dependence (FTND) [33] and the Wis-
consin Inventory of Smoking Dependence Motives,
30 items (WISDM-30) [34-36]. Nicotine withdrawal in the
Table 1 Overview of Health Education Counseling Sessions
Session Number Goal Topic
Randomization, Week
0 (30 minutes)
Establish rapport with participant-emphasizing willingness
to help them quit and encouraging their motivation/
confidence to quit smoking.
AA tobacco use, health risks, benefits of quitting, learning from
past quit attempts; and developing a plan for quit day.
Instructions of medication use as well as Identifying triggers
and managing withdrawal were also reviewed
Week 1 (15 minutes) Reinforce quit day plan, address medication use, identify
concerns, barriers, and strategies for success
If Quit: Rewarding yourself, recovering from slip, review
medication use or ending medication (week 7), managing
stress, alternatives to smoking, identify barriers, and living
smoke-free
Week 3 (20 minutes) Reinforce and encourage abstinence efforts. Identify
concerns, barriers, and strategies for successes
Week 5 (15 minutes)
Week 7 (20 minutes)
Week 16 (15 minutes) If still smoking: Review reasons for not quitting, review
reasons for quitting, discuss specific problems that lead to
relapse, and attempt to set a new quit plan
Weeks 0, 3, 7 conducted in person. Weeks 1, 5, 16 conducted via telephone.
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Withdrawal Scale (MNWS) [37]. The brief version of the
Questionnaire for Smoking Urges (QSU-brief) assessed
craving to smoke [38].
Psychosocial measures
The Center for Epidemiologic Studies Short Depression
Scale (CESD-10) assessed distress associated with depres-
sive symptoms [39,40]. The 2-item Patient Health Ques-
tionnaire (PHQ-2) was also used to identify primary
symptoms of depression over the past two weeks [41]. The
Perceived Stress Scale, 4 items (PSS-4) assessed self-
appraised stress experienced in the past month [42]. The
12-item Interpersonal Support Evaluation List (ISEL-12)
assessed global level of social support [43]. The Positive
and Negative Affect Scales (PANAS) were administered
to measure positive (e.g., alert, enthusiastic) and negative
(e.g., anger, fear) affective states [44]. We used the Experi-
ences of Discrimination (EOD) scale to assess the fre-
quency of self-reported discrimination because of race,
ethnicity or color [45,46]. The Reward Responsiveness
Scale of the Behavioral Inhibition System/Behavioral Acti-
vation Scale (BIS/BAS) assessed behavioral inhibition,
behavioral activation, and affective responses to impending
reward and punishment [47]. Smoking-related weight con-
cerns and confidence to maintain current weight after
quitting were assessed using the Meyers Weight Concerns
Table 2 KIS III Assessments
Assessment #
items
Ranges of
Scores
Eligibility Randomization
Week 0
Week
1
Week
3
Week
5
Week
7
Week
16
Week
26
Blood draw X X
Salivary cotinine X
Demographics 7 X X
Cigarette Data 5 X
Other Tobacco Use 1 X X X X
Smoking Status (cpd) 1 X X X X X X
Timeline Follow-back (TLFB) 7 X X X X
Smoking History 4 X
Quitting History 4 X
Weight Concerns:
Weight Concerns Scale, 6 1-6
Weight Self Efficacy Scale, 6 1-10 X
Adapted Myers Weight Concerns 2 0-11
Home Smoking Restrictions 5 X X
Work Place Smoking Restrictions 4 X
Motivation to Quit 1 1-10 X
Confidence to Quit 1 1-10 X
Nicotine Dependence (FTND) 6 0-10 X
Wisconsin Inventory of Smoking Dependence
Motives (WISDM-30)
30 10-70 X
Minnesota Withdrawal Scale (MNWS) 8 0-32 X X X X
Craving (QSU-Brief) 10 1-7 X X X X
Positive and Negative Affect (PANAS) 20 10-50 X X X X
Depression:
CES-Short Depression Scale (CESD-10), 10 0-30
2-item Patient Health Questionnaire (PHQ-2) 2 0-6 X X X X
Stress (PSS-4) 4 0-16 X
Social Support (ISEL-12) 12 12-48 X
Impulsivity 5 5-20 X
Racial Discrimination [45] 12 0-9 X
0-45
Racial/Ethnic Identity 8 X
Approximate duration of survey (in minutes) 10 45 5 15 5 15 5 10
Cox et al. Trials 2011, 12:22
http://www.trialsjournal.com/content/12/1/22
Page 5 of 12Scale [48], a modified version of the Weight Concerns
Scale [49], and the Weight Efficacy After Quitting scale
(WEAQ) [49].
Biochemical measures
Nicotine metabolism phenotype (3HC/COT ratio) and
genotype
Cytochrome P450 (CYP) 2A6 is the major enzyme
responsible for metabolizing nicotine into cotinine
(COT) and the further metabolism of COT to trans-3’-
hydroxycotinine (3HC) [50,51]. Cotinine, in turn, is
metabolized into trans-3’-hydroxycotinine (3HC) also by
CYP2A6 [51]. The half-life of nicotine (2 hours) is rela-
tively short compared to cotinine (16 hours) [52].
Trans-3’-hydroxycotinine (3HC) is formation dependent,
resulting in a half life that is the same as its parent coti-
nine (16 hours). Therefore, the ratio of 3HC to cotinine
is fairly constant over time [53]. The plasma 3HC/COT
ratio is highly correlated with total nicotine clearance
and CYP2A6 activity making it a useful biomarker of
the rate of nicotine metabolism [54]. Both the 3HC/
COT ratio and/or CYP2A6 genotype have been asso-
ciated with the number of cigarettes smoked per day
and the likelihood of quitting [27,55,56], although dispa-
rate findings suggest further study is needed particularly
among different racial/ethnic groups [57-60].
Bupropion metabolism phenotype and genotype
Bupropion acts, in part, by inhibiting norepinephrine
and dopamine reuptake [61]. Bupropion has three prin-
cipal metabolites: hydroxybupropion, threohydrobupro-
pion, and erythrohydrobupropion [62]. The mean
elimination half-lives for these metabolites are estimated
to be 20 hours for hydroxybupropion, 37 hours for
threohydrobupropion, and 33 hours for erythrohydrobu-
propion. These metabolites are known to be pharmaco-
logically active, although their relative activity is not
well established [29]. Following 150mg of sustained-
release bupropion every 12 hours, steady state plasma
concentrations for bupropion and metabolites are
reached within 8 days.
CYP2B6 metabolizes bupropion to its main metabolite
6-hydroxybupropion [63,64]. Genetic variation of
CYP2B6 alters enzyme activity [30,65-68], and genetic
variation in CYP2B6 has been associated with differ-
ences in smoking cessation outcomes [30].
Blood and Serum Collection
Blood samples were collected at two time points: Weeks
0 and 3. Samples were collected at Week 0 for evalua-
tion of nicotine metabolism phenotype (3HC/COT,
derived from nicotine from smoking) and both CYP2A6
and CYP2B6 genotype. Participants smoked one cigar-
ette of their usual brand: after 30 minutes, 20 ml of
blood was drawn into polypropylene containers- B-D
vacutainer containing 100 USP units Lithium Heparin,
mixed by inversion and centrifuged at room temperature
for 10-15 minutes. Plasma was extracted and stored at
-20° C. Following completion of data collection, plasma
samples will be thawed at room temperature and then
assayed by solid phase extraction followed by LC/MS/
MS [69] to evaluate nicotine, COT and 3HC using stan-
dard procedures [70,71]. For genotyping, 20 mls of
blood was collected into ACD tubes, mixed and then
transferred samples to 20 ml plastic scintillation vials
which were frozen at -20°C. CYP2A6 and CYP2B6 geno-
typing will use published gene and allele-specific poly-
merase chain reaction assays [4,31,51].
Week 3 was selected as the time point for the analysis
of bupropion metabolism phenotype, as participants
using active bupropion (n=270) will have 1) reached
steady state levels of bupropion, and 2) passed at least 7
days from their Quit Date, allowing us to evaluate
bupropion metabolism in relation to cotinine-confirmed
7-day point prevalence abstinence. Because participants
and study staff were blinded to treatment condition,
blood was collected from all participants. Participants
reported the date and time of their most recent medica-
tion dose and their daily use of study medication during
the previous 7 days, and the information were recorded
in relation to the date and time of blood draw. Follow-
ing completion of all participant data collection, follow-
up, and subsequent unblinding of randomization, phe-
notype analysis will be conducted for samples of partici-
pants from the active bupropion arm of the study only.
Salivary cotinine validation of smoking abstinence
The primary endpoint of this study is biochemically veri-
fied 7-day point prevalence smoking abstinence defined as
no cigarettes (not even a puff) in the previous 7 days at
Week 26, validated using salivary cotinine collected at
Week 26. This method is consistent with recommended
guidelines [72,73]. We used the cut-point of 15ng/ml coti-
nine to differentiate smokers from nonsmokers [73-75].
Salivary cotinine analysis was conducted using gas chro-
matography technique as described elsewhere [76].
Data analysis
Within this paper, we calculated descriptive summaries
of baseline (Week 0) demographic, psychosocial charac-
teristics and smoking history of the participants using
frequencies and percentages for categorical variables and
means and standard deviations for quantitative variables.
Phenotyping, genotyping, and evaluation of abstinence
outcomes will be presented in future manuscripts.
Results
An overview of screening and enrollment for KIS-III
is provided in Figure 1. Of 2,628 individuals who
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screened for eligibility, 999 (38%) were phone-eligible and
were scheduled for in-person screening. Radio was the
most common source of information about the study
(29%), followed by recruitment through the Swope clinic
(20%), television (17%), word of mouth (13%), and Tru-
man Medical Center (9%). Most of those screened (70%)
were ineligible for study participation with the primary
reasons for ineligibility being smoking >10 CPD, not
medically eligible, use of other forms of tobacco, and
binge drinking within the past 6 months. Of smokers
who passed phone eligibility, one third (370) did not keep
the final eligibility study appointment. Of those who
attended final eligibility screening (629), 89 (14%) were
not eligible for randomization. Five hundred and forty
(86% of those attending final eligibility screening) were
eligible, consented, and randomized to the bupropion or
placebo treatment group.
Participant randomization by month (from December
2007 to October 2009) is presented in Figure 2. The bar
graph represents monthly numbers of individuals
screened, those ineligible, those who did not keep
appointment and participants randomized, while the line
graph reflects cumulative enrolment over the study per-
iod. Participant enrollment was completed 7 weeks
ahead of the projected schedule.
Figure 1 Screening and enrollment of study participants.
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Participants.
Table 3 Participant Characteristics
Summary statistics Sample size (n)
Demographic Variables
Age, mean [SD] yr 46.5 (11.3) 540
Women, n (%) 357 (66.1) 540
Married or living with partner, n (%) 166 (30.8) 539
Monthly family income < $1800, n (%) 327 (60.7) 539
Education ≥ High school, n (%) 454 (84.2) 539
Weight, mean [SD] 195.5 (52.9) 539
BMI, mean [SD] 31.1 (7.9) 539
Psychosocial Variables
Depression (CESD-10), mean [SD] 7.7 (5.2) 539
Stress (PSS-4), mean [SD] 5.2 (3.2) 539
Tobacco Related Variables
Serum cotinine in ng/ml., mean [SD] 275.8 (155.8) 536
Exhaled carbon monoxide in p.p.m., mean [SD] 16.4 (10.0) 411
Cigarettes per day, mean [SD] 8.0 (2.5) 540
Time to first cigarette, ≤30 minutes, n (%) 390 (72.2) 540
FTND, mean [SD] 3.2 (1.7) 540
Smoke menthol cigarettes, n (%) 452 (83.7) 540
Number of previous 24 hour quit attempts in the past year, mean [SD] 3.7 (7.7) 540
Use of pharmacotherapy during the most recent quit attempt, n (%) 133 (24.2) 511
Age of first cigarette, mean [SD] yr 17.6 (5.9) 538
Age started smoking regularly, mean [SD] 21.1 (7.1) 538
Motivation to quit, mean [SD] 9.7 (0.8) 540
Confidence to quit, mean [SD] 7.9 (2.4) 540
Smoke-free household, n (%) 132 (24.4) 540
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study participants. Participants had a mean age of 46.5
years, the majority, (66.1%) were women, one in three
were married or living with a partner, and over 84% had
obtained a high school degree. Almost two in three
earned less than $1,800 monthly. Participants smoked
an average of 8.0 cigarettes per day, had a mean exhaled
carbon monoxide of 16.4ppm with a range of (1-55), a
mean cotinine of 275.8ng/ml. Mean Body Mass Index
(BMI) was 31.1. Over 72% smoked within 30 minutes of
waking with a mean FTND dependence score of 3.2
with a range of (0-7). Most (83.7%) reported smoking
menthol cigarettes. Only 24.4% reported living in a
smoke-free household. The average number of quit
attempts in the past year was 3.7 and 24.2% reported
using pharmacotherapy during their most recent quit
attempts. Motivation and confidence to quit were high.
These demographic and smoking history characteristics
are similar to African American light smokers from our
previous KIS-II trial [22].
Retention of participants for Weeks 1, 3, 5, 7, 16, and
26 was 90.6%, 78.7%, 75.7%, 72.8%, 67.6%, and 70.2%,
respectively. Of six total counseling sessions, participants
completed a mean (SD) of 4.85 (1.49) sessions.
Discussion
The Kick It at Swope III (KIS-III) trial was designed as
the first treatment study of bupropion for African
American light smokers. To date, KIS-III is the fourth
study to evaluate pharmacotherapy for light smokers
[22,77,78] and the second to evaluate treatment for
African American light smokers [22]. KIS-III is also the
first study to examine both nicotine and bupropion
metabolism, evaluating CYP2A6 and CYP2B6 phenotype
and genotype as possible predictors of outcome, within
the context of treatment of African American smokers.
Collecting data on metabolism and genotype allows us
to evaluate biological mechanisms in conjunction with
psychosocial and smoking data to further advance our
understanding of African American smoking behavior
and ultimately enhance treatment outcomes.
We have demonstrated the feasibility of recruiting and
enrolling African American light smokers into a clinical
treatment trial involving biological data collection and
genetic analysis. These feasibility findings are consistent
with studies that have successfully enrolled African
American smokers for treatment and provide further evi-
dence of willingness to share genetic information within
a research study of smoking behavior [19,79]. KIS-II
enrolled smokers into a cessation trial but conducted the
genetic portion of the study using a second consent pro-
cess. In KIS-II, there was 83% participation in the genetic
portion of the study [79]. Based in part on this excellent
consent rate, indicating consent for genetic analysis
posed little barrier to enrollment, KIS-III included
genetic analysis as part of overall study participation and
enrolled accordingly. Participants were informed during
screening about the goals of the study, the requirement
of multiple collections of biological samples, and the
rationale for collecting such data. This information was
reviewed in further detail within the consent process. Of
1629 individuals who completed any screening for study
participation, only 18 (1.1%) were ineligible to participate
in the study because they refused blood draws, suggesting
that the inclusion of phenotype and genotype assess-
ments did not impede recruitment in this African Ameri-
can population. Factors that contributed to recruitment
success may include conducting this research within a
trusted community medical setting, having an established
history of smoking cessation treatment and research
within the community, and using a multi-method
approach to recruitment. The current data add to the lit-
erature demonstrating support for inclusion of African
American smokers in smoking cessation treatment stu-
dies, in genetic investigation of tobacco use and treat-
ment, and more broadly in cancer control research.
Consistent with our previous KIS trials, study partici-
pants were largely low income and predominantly
menthol cigarette smokers. Despite excluding individuals
currently using pharmacotherapy for the treatment of
depression, we found approximately one third of partici-
pants reported symptoms of depression. As other
research has shown bupropion to reduce negative mood
during smoking cessation treatment [80,81] and to be
effective in supporting abstinence in moderate to heavy
smokers with or without a history of depression [82], we
are planning analyses examining changes in mood and
depression in relation to smoking behavior within the
current sample of African American light smokers.
Importantly, while low income, use of menthol, and
depression previously have been associated with poorer
smoking cessation treatment outcomes [21,83-87], this
sample was highly motivated to stop smoking. Our pre-
vious KIS-II trial found health education counseling
contributed to higher rates of abstinence in highly moti-
vated African American light smokers, when compared
to motivational counseling [22]. The finding that smo-
kers in the current trial show similarly high levels of
motivation provided support for the use of health edu-
cation counseling within the current study.
Examination of KIS-III screening data points to some
limitations related to generalizability and recommenda-
tions for needed research. Over half of individuals who
expressed interest in enrolling in this smoking cessation
s t u d yw e r ei n e l i g i b l et ou s eb u p r o p i o na c c o r d i n gt o
study protocol. Future research should examine other
pharmacotherapy for light smokers, such as varenicline,
which has been found to be effective in moderate to
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Page 9 of 12heavy smokers (>10cpd) [18]. Findings also showed over
one third of interested smokers screened in KIS-III
reported use of other forms of tobacco and were
excluded from treatment. While smoking cessation clini-
cal trials typically exclude smokers who report use of
other forms of tobacco, future studies may provide
greater generalizability by examining tobacco use treat-
ment more broadly defined. Inclusion of smokers who
use other forms of tobacco would require consideration
of appropriate measures of tobacco use and abstinence
verification.
In summary, the KIS-III study provides a unique
opportunity to evaluate psychosocial and biological
mechanisms related to drug use and treatment outcomes
in African-American light smokers. Baseline findings
support the feasibility of enrolling African American light
smokers in a treatment study involving genetic analysis.
Identifying individuals for whom treatments are most
effective and, in contrast, identify characteristics related
to relapse risk will contribute to advancing tailored
tobacco use treatment, with the ultimate goal of enhan-
cing treatment and reducing tobacco-related health dis-
parities for African-American smokers.
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